Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

Conditions

Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period. — DRUG
This is an FDA approved drug. The participants will be educated on the potential instillation site sensation that may occur as reported from the Pivotal Trials and that the sensation may differ between eyes due to the Neurotrophic Keratopathy. Qualified eyes must meet the inclusion and exclusion criteria. If both eyes qualify, then the one with the worst vision will be the study eye. If both eyes have equal visual acuity then the right eye will be the study eye.
Alternative would be patient exiting the trial and starting on tears or other standard of care. — OTHER
This is an open label trial. If the patient does not do well on Acoltremon Ophthalmic Solution, then the participant will be removed from trial and put on standard of care treatment, other than Acoltremon.

STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.

Other: Acoltremon 0.003% Ophthalmic Solution
Open Label treatment of Acoltremon

Unanesthetized Schirmer Test [ Time Frame: 8 weeks ]

Facility	City	State	ZIP	Site coordinators
University of South Florida/Ophthalmology	Tampa	Florida	33612	Angie Windham [email protected] 813-974-1423 Susan Sherouse [email protected] 813-974-0948 Pedram Hamrah, MD (PRINCIPAL_INVESTIGATOR)

By research site